In this study, the focus is on obesity as a key risk factor. The impact of this condition on the incidence and outcomes of breast cancer varies depending on menopausal status: for premenopausal women, a high body mass index (BMI) is associated with a lower risk, while for postmenopausal women, it is associated with an increased risk.
Experts, taking into account the specifics of the epidemiological situation and the healthcare system in Kyrgyzstan, conducted an in-depth analysis of the current state of the problem, identifying key challenges and proposing ways to improve the prevention, diagnosis, and treatment of breast cancer.
The aim of the study was to provide a comprehensive overview of the epidemiology of breast cancer, justify the clinical significance of molecular subtypes, and analyze how obesity and age are related to the risk and outcomes of the disease, especially in the context of data from Kyrgyzstan.
To conduct the analysis, publications from peer-reviewed journals and reports from relevant organizations (including PubMed, Cochrane, WHO, SEER, GLOBOCAN) from 2013 to 2024 were studied. A comprehensive approach was used, integrating epidemiology, biology of subtypes, risk factors, and organization of medical care.
The results showed that among the subtypes of breast cancer, luminal forms prevail; the triple-negative subtype is less common but constitutes a significant proportion of early recurrences. The relationship between BMI and disease risk depends on menopausal status.
According to GLOBOCAN data, from 2020 to 2022, approximately 2.3 million new cases of breast cancer were recorded worldwide each year. In Kyrgyzstan, the standardized incidence rate is lower than the average in Central Asia, but there is a trend towards growth.
The researchers concluded that the biological heterogeneity of breast cancer and modifiable risk factors require targeted prevention and coordinated clinical pathways. The key directions for Kyrgyzstan are:
- increasing screening coverage;
- monitoring lifestyle factors;
- ensuring access to immunohistochemistry and genetic testing;
- developing routing for patients with aggressive subtypes for timely specialized care.
Breast Cancer
Download Document
